AI & Data Analytics

How Oklahoma’s Center for Health Systems Innovation is changing rural healthcare.

Direct-to-consumer tests could improve medicine, but healthcare must prepare for the adverse effects.

From the farm to the Oval Office to the clinic, AI must account for context.

Northwell Health explains how it implemented self-service analytics.

Janae Sharp joins Data Book to discuss the shortcomings of interoperability.

Why you can’t ignore data, analytics, and value-based care.

The precertification model would apply to med-tech orgs of all sizes.

The agency released a strategic plan and intends to hire a data chief. Why?

Silos prevent scientific advancements from flowing into the clinic quickly, the agency says.

DreaMed Diabetes aims to personalize disease management.

The NIH’s All of Us program is just one example of what’s to come.

News and insights on cyberwarfare, the Apple Watch, wearables, and more.

This week on Data Book, the first human killed by a robot and the murky question of AI and legal liability.

How sophisticated simulations brought researchers to a critical chemical.

Value-based care at the heart of new guidances, and, as usual, they came with Gottlieb tweets.

"It could lead to a whole new field of investigation in clinical and physiological sciences and reshape our understanding of human physiology."

The new partnership also calls for closer drug discovery collaboration between WuXi AppTec and Insilico Medicine.

European leaders are investing in AI in an effort to catch up with the US and Asia.

Head still spinning from the Apple API news? Can’t quite keep up with the latest in health-tech studies? HCA News is here for you.

How wearable devices (and the data they churn out) could revolutionize medicine.

The capture of the alleged Golden State Killer might lead to justice for his victims and families. But many question the ethics of the measures police used to identify and put him behind bars.

How the start-up hopes its software platform will transform R&D.

It led to “missed opportunities” during the ACA rollout and a key time in the opioid epidemic.

The burgeoning gen-editing giant will test its zinc finger nuclease (ZFN) editing technology against lysosomal storage disorders in children.

The company plans to have a fully functional version commercialized in just a few months.